openPR Logo
Press release

Registration Opens for the 9th annual Biosimilars and Biobetters 2018 conference

06-20-2018 05:36 PM CET | Health & Medicine

Press release from: SMi Group

biosimilars, biobetters,

biosimilars, biobetters,

SMi Reports: Registration for SMi’s 9th annual Biosimilars and Biobetters conference has opened and the brochure is available to download

SMi Group is proud to announce the return of the 9th annual Biosimilars and Biobetters conference, taking place on the 26th and 27th September 2018 in London, UK. Registration for the event is now open and the newly released brochure is available to download from the event website. This year’s conference will have a focus on forecasting the next wave of biosimilars to ensure optimal market commercialisation.

The two-day event promises a diverse expert speaker line-up and will bring together a global audience of biosimilar experts to discuss the latest developments, as well as the future of the rapidly evolving and expanding biosimilars market.

Biosimilars and Biobetters 2018 event highlights:
• Hear topical case studies from industry thought leaders with marketed biosimilars
• Assess whether marketed biosimilars are successful contenders and if they have sparked a competitive environment
• Evaluate if enough has been done to convince the payer, prescriber and patient to switch
• Discuss the next waves of biosimilars entering the market to learn which biosimilars to include in your pipeline
• Consider the possibility of biosimilar orphan drugs

The conference will feature presentations from industry experts at leading pharmaceutical companies, including:
• Erin Federman, Head of Biologics, Europe, Mylan
• Michael Muenzberg, Member, Comparative Outcomes Group and Former EU Medical Director, Biosimilars, Amgen
• Ekkehard Brockstedt, Team Leader Outsourced Trials, Boehringer Ingelheim
• Meenu Wadhwa, Section Leader, Cytokines and Growth Factors, Biotherapeutics Group, NIBSC, MHRA
• Any many more…

After many years of rejection, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars, as seen in more tolerant legislation and increased use and approval of biosimilars across the globe. Biosimilars and Biobetters 2018 will explore the thoughts of industry thought leaders and assess the success of marketed biosimilars, as well as discussing the current attitudes of potential customers, prescribers and patients towards biosimilars and biobetters.

Download the newly released brochure and view the full 2018 agenda on the website at: www.biosimilars-europe.com/

Book by 29th June and receive a £300 discount

Interested in sponsoring, exhibiting or speaking at this event?

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

Biosimilars and Biobetters
26th – 27th September 2018
Copthorne Tara Hotel, Kensington, London, UK
www.biosimilars-europe.com/

Contact e-mail: ssapal@smi-online.co.uk
Contact tel: +44 (0) 207 827 6000

---- END ----
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

SMi Group
1 Westminster Bridge Road
London
SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Registration Opens for the 9th annual Biosimilars and Biobetters 2018 conference here

News-ID: 1091066 • Views:

More Releases from SMi Group

Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug Discovery Conference
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK. The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines. Darren Green, Director of Computational Chemistry at GSK will be chairing at
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,

All 5 Releases


More Releases for Biosimilars

Global Biosimilars Market 2021-2028 | Price Advantage of Biosimilars Over Biolog …
The global Biosimilars market focuses on encompassing major statistical evidence for the Biosimilars industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Biosimilars study also shifts its attention with an in-depth
Growth of the Biosimilars Market Is Mainly Driven by Increasing Number of Approv …
A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Oral Biologics and Biosimilars Market | Global Oral Biologics and Biosimi …
The oral biologics and biosimilar market contain of sales of oral biologics and biosimilar products and associated services utilized to treat chronic syndromes such as diabetes, arthritis, cancer. Biologics are drugs completed from living cells using exceedingly complex technology while biosimilars are generated to function similarly to biologics but are not matching to biologics. Biosimilars offer energetic properties as any licensed biologic drug. The oral biologics and biosimilar market encompass
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million